Corcept Therapeutics (CORT) Receivables - Other (2019 - 2025)

Corcept Therapeutics (CORT) has 7 years of Receivables - Other data on file, last reported at $3.9 million in Q3 2025.

• For the quarter ending Q3 2025, Receivables - Other rose 34.48% year-over-year to $3.9 million; the trailing twelve-month figure through Dec 2025 stood at -$14.0 million (changed N/A YoY), and the FY2025 full-year result was $4.1 million, up 129.29% from the prior year.
• Receivables - Other retreated to $3.9 million in Q3 2025, from $4.1 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $18.2 million in Q1 2025 to a low of -$14.0 million in Q1 2024.
• A 5-year average of $5.1 million and a median of $2.6 million in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other surged 1455.56% in 2023 and slumped 200.0% in 2024, its largest moves.
• Tracing CORT's Receivables - Other over 5 years: stood at $1.4 million in 2021, then surged by 900.0% to $14.0 million in 2022, then changed by 0.0% to $14.0 million in 2023, then slumped by 79.29% to $2.9 million in 2024, then soared by 34.48% to $3.9 million in 2025.
• Business Quant data shows CORT's Receivables - Other at $3.9 million in Q3 2025, $4.1 million in Q2 2025, and $18.2 million in Q1 2025.